Sweden
· Delayed Price · Currency is SEK Diagonal Bio AB Statistics
Total Valuation
Diagonal Bio AB has a market cap or net worth of SEK 13.36 million. The enterprise value is 8.86 million.
| Market Cap | 13.36M |
| Enterprise Value | 8.86M |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Diagonal Bio AB has 1.21 billion shares outstanding.
| Current Share Class | 1.21B |
| Shares Outstanding | 1.21B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 13.13% |
| Owned by Institutions (%) | 3.57% |
| Float | 1.01B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.88 |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.94 |
| EV / Sales | 6.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45
| Current Ratio | 2.45 |
| Quick Ratio | 1.83 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.64 |
Financial Efficiency
Return on equity (ROE) is -40.60% and return on invested capital (ROIC) is -24.71%.
| Return on Equity (ROE) | -40.60% |
| Return on Assets (ROA) | -19.37% |
| Return on Invested Capital (ROIC) | -24.71% |
| Return on Capital Employed (ROCE) | -32.49% |
| Revenue Per Employee | 270,600 |
| Profits Per Employee | -1.89M |
| Employee Count | 5 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.94% in the last 52 weeks. The beta is -1.88, so Diagonal Bio AB's price volatility has been lower than the market average.
| Beta (5Y) | -1.88 |
| 52-Week Price Change | -65.94% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 43.75 |
| Average Volume (20 Days) | 8,375,674 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diagonal Bio AB had revenue of SEK 1.35 million and -9.47 million in losses.
| Revenue | 1.35M |
| Gross Profit | 1.02M |
| Operating Income | -9.22M |
| Pretax Income | -9.47M |
| Net Income | -9.47M |
| EBITDA | -7.92M |
| EBIT | -9.22M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 4.50 million in cash and n/a in debt, giving a net cash position of 4.50 million or 0.00 per share.
| Cash & Cash Equivalents | 4.50M |
| Total Debt | n/a |
| Net Cash | 4.50M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 28.39M |
| Book Value Per Share | n/a |
| Working Capital | 3.79M |
Cash Flow
| Operating Cash Flow | -22.61M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 75.68% |
| Operating Margin | -681.67% |
| Pretax Margin | -699.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Diagonal Bio AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -70.86% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |